Sio Capital Management, LLC In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Sio Capital Management, LLC reported 43 stock positions worth $265.1 million . Its top holding was Labcorp (LH) at 18.9% of the portfolio, followed by Teleflex (TFX, 8.8% ) and Zimmer Biomet (ZBH, 6.4% ). Compared with Q1 2024, it opened 13 new positions, sold out of 15, added to 11 and reduced 8. The biggest buy was Teleflex (TFX, shares +228% ) and the biggest sale an exit from Globus Medical Class A (GMED).
Location NEW YORK, NY
CIK 0001482416
Portfolio Value $265.1M (Q2 2024) Holdings 43 stocks · $265.1M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q1 2024 LH Labcorp Holdings Inc. 245,902 $50.0M Add +8.8% TFX Teleflex Inc. 111,078 $23.4M Add +227.9% ZBH Zimmer Biomet Holdings Inc. 155,304 $16.9M Add +109.4% SNN Smith & Nephew PLC -Spon ADR 579,619 $14.4M New OGN Organon & Co. 608,096 $12.6M Add +26.9% GSK GSK PLC-Spon ADR 312,000 $12.0M Add +18.4% CRBP Corbus Pharmaceuticals Holdi 225,165 $10.2M New VXRT Vaxart Inc. 14,764,991 $9.9M New TYRA Tyra Biosciences Inc. 600,294 $9.6M Add +12.1% ABT Abbott Laboratories 89,500 $9.3M New CI The Cigna Group 26,786 $8.9M Reduce -64.8% KVUE Kenvue Inc. 485,000 $8.8M New IRON Disc Medicine Inc. 192,000 $8.7M New ERAS Erasca Inc. 2,874,536 $6.8M Add +18.4% BDSX Biodesix Inc. 4,347,855 $6.7M New ATXS Astria Therapeutics Inc. 510,267 $4.6M Add +24.4% ANIP Ani Pharmaceuticals Inc. 71,740 $4.6M Reduce -17.9% BLCO Bausch + Lomb Corp. 302,710 $4.4M New PMVP PMV Pharmaceuticals Inc. 2,708,408 $4.4M New ZYME Zymeworks Inc. 491,128 $4.2M New BBIO Bridgebio Pharma Inc. 125,174 $3.2M Reduce -38.4% APGE Apogee Therapeutics Inc. 78,000 $3.1M No change CNTX Context Therapeutics Inc. 1,328,352 $2.7M New MODULAR MED INC 1,539,352 $2.4M No change STOK Stoke Therapeutics Inc. 175,301 $2.4M Reduce -22.3% ENTA Enanta Pharmaceuticals Inc. 177,004 $2.3M No change THRD Third Harmonic Bio Inc. 163,363 $2.1M No change NUVB Nuvation Bio Inc. 668,115 $2.0M Reduce -50.0% SPRY Ars Pharmaceuticals Inc. 217,864 $1.9M Reduce -59.4% VTYX Ventyx Biosciences Inc. 778,924 $1.8M Add +106.1% CMPS Compass Pathways PLC 293,417 $1.8M New ARQT Arcutis Biotherapeutics Inc. 159,626 $1.5M Reduce -74.9% XFOR X4 Pharmaceuticals Inc. 2,499,800 $1.4M Reduce -30.3% PRLD Prelude Therapeutics Inc. 320,394 $1.2M No change APRE Aprea Therapeutics Inc. 276,603 $1.1M No change RAPT THERAPEUTICS INC 315,000 $961K No change AVTX Avalo Therapeutics Inc. 71,458 $891K Add +604.0% FHTX Foghorn Therapeutics Inc. 121,672 $700K No change BOLD Boundless Bio Inc. 162,058 $627K Add +13.3% VSTM Verastem Inc. 133,412 $398K New NYXH Nyxoah SA 50,839 $354K No change NXTC Nextcure Inc. 130,000 $207K No change ASLAN PHARMACEUTICALS LTD 254,150 $76K No change
Options reported separately and not counted above: INSM puts ($91.3M), PCRX puts ($13.0M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $100K (not counted above) Security Class Shares / Principal Value Change HUMAW Humacyte Inc.-CW27 *W EXP 08/27/202 49,998 $70K No change RCKTW Rocket Pharmaceuticals in-27 *W EXP 09/02/202 400,000 $29K No change CMXWQ Caremax-CW *W EXP 06/08/202 12,808 $200 No change
Total filed on the 13F, all lines: $265.2M.
Portfolio Sells Q1 2024 → Q2 2024 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▲ GMED Globus Medical Inc. Class A Sold out 0.00% −7.35 CI The Cigna Group Reduce -64.8% 3.34% −6.29 MDGL Madrigal Pharmaceuticals Inc. Sold out 0.00% −4.75 MDT Medtronic PLC Sold out 0.00% −3.19 EMBC Embecta Corp. Sold out 0.00% −2.71 HUMA Humacyte Inc. Sold out 0.00% −2.17 HCSG Healthcare Services Group Sold out 0.00% −1.83 FUSN Fusion Pharmaceuticals Inc. Sold out 0.00% −1.81 SRRK Scholar Rock Holding Corp. Sold out 0.00% −1.69 IART Integra Lifesciences Holding Sold out 0.00% −1.69 ARQT Arcutis Biotherapeutics Inc. Reduce -74.9% 0.56% −1.64 OCUL Ocular Therapeutix Inc. Sold out 0.00% −1.21 CTMX Cytomx Therapeutics Inc. Sold out 0.00% −1.21 SPRY Ars Pharmaceuticals Inc. Reduce -59.4% 0.70% −1.21 XFOR X4 Pharmaceuticals Inc. Reduce -30.3% 0.55% −1.19 BBIO Bridgebio Pharma Inc. Reduce -38.4% 1.20% −0.99 NUVB Nuvation Bio Inc. Reduce -50.0% 0.74% −0.96 RVNC Revance Therapeutics Inc. Sold out 0.00% −0.80 IDYA Ideaya Biosciences Inc. Sold out 0.00% −0.50 IRWD Ironwood Pharmaceuticals Inc. Sold out 0.00% −0.45 ANIP Ani Pharmaceuticals Inc. Reduce -17.9% 1.72% −0.38 VINCERX PHARMA INC Sold out 0.00% −0.18 STOK Stoke Therapeutics Inc. Reduce -22.3% 0.89% −0.17
Portfolio Buys Q1 2024 → Q2 2024 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q1 2024 % Of Portfolio Change To Portfolio ▼ TFX Teleflex Inc. Add +227.9% 8.81% +6.14 SNN Smith & Nephew PLC -Spon ADR New 5.42% +5.42 CRBP Corbus Pharmaceuticals Holdi New 3.84% +3.84 VXRT Vaxart Inc. New 3.72% +3.72 ABT Abbott Laboratories New 3.51% +3.51 KVUE Kenvue Inc. New 3.33% +3.33 IRON Disc Medicine Inc. New 3.26% +3.26 ZBH Zimmer Biomet Holdings Inc. Add +109.4% 6.36% +2.95 BDSX Biodesix Inc. New 2.51% +2.51 LH Labcorp Holdings Inc. Add +8.8% 18.88% +1.68 BLCO Bausch + Lomb Corp. New 1.66% +1.66 PMVP PMV Pharmaceuticals Inc. New 1.66% +1.66 OGN Organon & Co. Add +26.9% 4.75% +1.61 ZYME Zymeworks Inc. New 1.58% +1.58 CNTX Context Therapeutics Inc. New 1.00% +1.00 ERAS Erasca Inc. Add +18.4% 2.56% +0.82 CMPS Compass Pathways PLC New 0.67% +0.67 GSK GSK PLC-Spon ADR Add +18.4% 4.53% +0.60 TYRA Tyra Biosciences Inc. Add +12.1% 3.62% +0.56 AVTX Avalo Therapeutics Inc. Add +604.0% 0.34% +0.26 VSTM Verastem Inc. New 0.15% +0.15 VTYX Ventyx Biosciences Inc. Add +106.1% 0.68% −0.05 ATXS Astria Therapeutics Inc. Add +24.4% 1.75% −0.26 BOLD Boundless Bio Inc. Add +13.3% 0.24% −0.47
Options Activity Q1 2024 → Q2 2024 Security Type Change vs Q1 2024 Underlying Shares Value ▼ PCRX Pacira Biosciences Inc. put Add +306.7% 455,500 $13.0M IRWD Ironwood Pharmaceuticals Inc. put Sold out 970,800 $8.5Mbefore exit
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 55 $583.5M AVR, COR, MMS, ALLO, GMED Q1 2026 71 $693.9M MMS, WAY, ICLR, COR, DNTH Q4 2025 63 $603.1M CELC, CI, SNY, MMS, ZBH Q3 2025 49 $395.1M MMS, CELC, SNY, DNTH, ALKS Q2 2025 47 $249.1M MMS, IRON, GMED, CNC, MRK Q1 2025 51 $330.2M ICLR, MMS, MRK, ZBH, NBIX Q4 2024 49 $355.3M ICLR, MMS, CI, LH, SNY Q3 2024 35 $223.1M LH, TEVA, MMS, ZBH, VXRT Q2 2024 43 $265.1M LH, TFX, ZBH, SNN, OGN Q1 2024 45 $287.0M LH, CI, GMED, MDGL, GSK